Galectin Therapeutics Inc. (GALT)

Market Cap	85.09M
Revenue (ttm)	n/a
Net Income (ttm)	-47.20M
Shares Out	63.18M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,814
Open	1.370
Previous Close	1.380
Day's Range	1.310 - 1.370
52-Week Range	0.730 - 3.780
Beta	0.79
Analysts	Hold
Price Target	n/a
Earnings Date	May 14, 2025

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Ther...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: GALT
• Website: https://galectintherapeutics.com